
Profound Medical Corp. PROF
$ 6.97
0.72%
Quarterly report 2026-Q1
added 05-07-2026
Profound Medical Corp. Accounts Receivables 2011-2026 | PROF
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Profound Medical Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.2 M | 7.04 M | 7.29 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.29 M | 7.04 M | 7.18 M |
Quarterly Accounts Receivables Profound Medical Corp.
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.42 M | 8.17 M | 4.9 M | 5.97 M | - | - | - | - | - | - | - | - | - | 17 K | - | - | - | 25 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.42 M | 17 K | 4.75 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
57.2 M | - | - | $ 3.31 B | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
6.55 M | $ 11.7 | 4.46 % | $ 331 M | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
97.3 M | $ 8.23 | -0.12 % | $ 1.24 B | ||
|
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
18.6 M | $ 4.33 | 1.88 % | $ 162 M | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | ||
|
LivaNova PLC
LIVN
|
216 M | $ 73.64 | -0.09 % | $ 4.02 B | ||
|
LENSAR
LNSR
|
6.38 M | $ 5.95 | 1.19 % | $ 71.2 M | ||
|
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
70 K | $ 2.36 | 2.16 % | $ 52 M | ||
|
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.46 | -2.09 % | $ 28.6 M | ||
|
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 18.43 | -0.38 % | $ 432 M | ||
|
Delcath Systems
DCTH
|
11.7 M | $ 11.45 | 1.96 % | $ 410 M | ||
|
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.01 | 1.0 % | $ 17.1 M | ||
|
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | ||
|
MiMedx Group
MDXG
|
75.7 M | $ 3.61 | -4.75 % | $ 534 M | ||
|
Pulmonx Corporation
LUNG
|
12.1 M | $ 1.54 | - | $ 62.7 M | ||
|
Electromed
ELMD
|
24.7 M | $ 38.58 | 2.23 % | $ 326 M | ||
|
Myomo
MYO
|
4.1 M | $ 0.95 | 3.85 % | $ 39.8 M | ||
|
Butterfly Network
BFLY
|
26.7 M | $ 4.48 | 2.05 % | $ 1.11 B | ||
|
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | ||
|
Sintx Technologies
SINT
|
178 K | $ 2.3 | 5.99 % | $ 6.38 M | ||
|
Orthofix Medical
OFIX
|
136 M | $ 10.41 | -14.32 % | $ 412 M | ||
|
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
679 M | $ 84.61 | 0.69 % | $ 11.4 B | ||
|
Insulet Corporation
PODD
|
141 M | $ 156.89 | 0.19 % | $ 11 B | ||
|
TransMedics Group
TMDX
|
84.3 M | $ 68.85 | 1.25 % | $ 2.34 B | ||
|
CONMED Corporation
CNMD
|
248 M | $ 37.02 | 0.03 % | $ 1.15 B | ||
|
Inspire Medical Systems
INSP
|
120 M | $ 44.74 | 1.36 % | $ 1.31 B | ||
|
Integer Holdings Corporation
ITGR
|
346 M | $ 90.0 | -1.63 % | $ 3.13 B | ||
|
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
660 M | $ 83.2 | 0.28 % | $ 48.7 B |